Skip to main content

ICMR Govt.of India, and Sun Pharma joined in public private partnership for Maleria Free India

 

Clinical courses

Indian Council of Medical Research (ICMR), Ministry of Health & Family Welfare (MOHFW), Govt. of India, Govt. of Madhya Pradesh and Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies), today, announced India’s first public-private-partnership agreement for Malaria Free India and other innovation in preventive health. This was announced by Dr Soumya Swaminathan, Director General –  ICMR, Principal Secretary Health Mrs. Gauri Singh Govt of Madhya Pradesh and Dilip Shanghvi, Managing Director, Sun Pharma as a unique effort to draw public – private sector collaboration in promoting  preventive health measures. The publicprivate-partnership stakeholders will jointly undertake malaria control & elimination programme by setting-up Management & Technical Committees to provide oversight for disease surveillance & elimination.

Under the aegis of this unique public-private-partnership, ICMR, MOHFW, Govt. of India, Govt of Madhya Pradesh and Sun Pharma will establish a malaria elimination demonstration

project titled Malaria Free India, to support the national framework for elimination of malaria in India. The demonstration project will be launched in one of the most malaria endemic districts of Madhya Pradesh and implemented in a phased manner, beginning with Mandla district of Madhya Pradesh. The public-private-partnership  stakeholders will execute the malaria elimination programme over a span of 3 to 5 years covering over 1,200 villages in Mandla district.

According to the Hon’ble Union Minister of Health & Family Welfare, Sh J P Nadda adds, "The first of its kind public-private-agreement between ICMR & Sun Pharma reiterates India's commitment to eliminate malaria. Implementing Malaria elimination demonstration project in a high transmission district of Mandla in Madhya Pradesh using proven case management and vector control strategies will be done in collaboration and through the support of Govt of Madhya Pradesh. ICMR and Sun Pharma will aim to reduce the morbidity and mortality caused by malaria in this demonstration project as well as prevention of re-introduction of malaria.  The lessons learned would be used for elimination of malaria from the country by the national program. I believe that this partnership has a potential to create sustainable impact by reducing malaria morbidity and improving people's health. This will enable us to alleviate poverty within the target geographies through cost effective interventions and improvement of overall development and quality of life.”

The Minister Health & Family Welfare; Ayush; Bhopal Gas Rehabilitation; Medical Education and Legislative Affairs, Govt of Madhya Pradesh, Dr Narottam Mishra adds, "We are very happy to collaborate with Sun Pharma and ICMR  in their efforts at elimination of Malaria from the State. There are over 5,000 villages in Madhya Pradesh, with API over 1 and it is our endeavour to move the State and especially the malaria endemic districts towards API below 1. This requires not just strong efforts at community level but also ensuring and maintaining the supply chain for malaria drugs and diagnostics, right up to the villages. I hope that this collaboration, which is starting from district Mandla, will expand to other districts and enable us to achieve the ambitious goals we have set for ourselves."  

According to the Director General Indian Council of Medical Research, Dr. Soumya Swaminathan, “I am pleased that ICMR is partnering with Sun Pharma in a malaria elimination demonstration project – a high priority for us. Malaria is not uniformly distributed in India and 6 states are responsible for > 60 % malaria in the country. These are Odisha, Chhattisgarh, Madhya Pradesh, Jharkhand, Maharashtra and Northeastern states.  91 districts in India, having 5% of country’s total population, 31 % of tribal population  are high Burden districts contributing nearly half of malaria cases and deaths. Studies done by ICMR have shown that a holistic strategy can reduce malaria burden significantly within a few years, in a defined area. The proposed public-private partnership for malaria elimination will use the same available and tested strategies of case management (diagnosing and treating all symptomatic and asymptomatic cases through mass screening), intense.

surveillance and vector control by using indoor residual sprays and long-lasting insecticide impregnated bednets. Community participation and IEC will be key components. This project aims to demonstrate that it is feasible to eliminate malaria from a high endemic district, and will hopefully become a pathfinder for the rest of the country. It is also a unique model of collaboration between the central and state governments, a private pharma company and ICMR, and could pave the way for more private investment in public health."

Commenting on its Malaria Free India public-private-partnership initiative, Mr Dilip Shanghvi, Managing Director, Sun Pharma said, “Malaria is a major public health problem. It is known to impede development, saving and investment as well as worker productivity in the form of absenteeism. All this has an adverse impact on per-capita gross domestic product.  Moreover, there is a strong correlation between malaria and poverty. Malaria endemic countries have shown significantly lower rates of economic growth.  Through our Malaria Free India initiative we aim to achieve zero malaria incidences in more than 1,200 villages of Mandla district of Madhya Pradesh by FY21. The experience gained from  Mandla project will guide the development of broader plans for malaria elimination in Madhya Pradesh as well as other high malaria endemic States in India.”

The Malaria Free India public-private-partnership initiative is governed by six-point-goals:

  1. Demonstrate feasibility of malaria elimination in Mandla district of Madhya  Pradesh.
  2. Eliminate malaria-attributable deaths in infants, children and pregnant women.
  3. Sustain malaria-free Mandla district.
  4. Strengthen existing health systems.
  5. Introduce mobile-based surveillance systems and treat all malaria cases as per National Vector Borne Disease Control Program (NVBDCP) guidelines.
  6. Mobilize communities by using Information, Education, and Communication tools. 

To demonstrate the feasibility of eliminating malaria and prevention of re-establishment of this disease ICMR,  Ministry of Health & Family Welfare, Govt. of India, Govt of Madhya Pradesh and Sun Pharma will use rapid diagnostic tests, prompt treatment of effective antimalarial drugs, long-lasting insecticide treated bednets and indoor residual spray for achieving elimination of malaria.

The Malaria Free India public-private-partnership initiative will also demonstrate health benefits of clean environment as envisioned by Swachh Bharat Abhiyaan initiative.  The project team will work with local Panchayats  on the usefulness of eliminating water bodies around households. The significant deliverable of this particular component of the project will be to reduce mosquito breeding sites in the project districts. As part of the project implementation plan, recommendations will be made for improving health systems and services.  The results of this evaluation would aid private and governmental agencies to better target aid to Primary Health Centers.

For operationalizing the Malaria Free India goals, Sun Pharma will establish a not-for-profit foundation. This Foundation will operate as an independent entity by engaging national and international experts as knowledge partners for the project while remaining accountable to the Malaria Free India public-private-partnership stakeholders.  The Malaria Free India demonstration project is in line with Sun Pharma's CSR efforts for holistic development of underserved communities in a sustainable and impactful manner. This unique Malaria Free India publicprivate-partnership gives Sun Pharma an opportunity to play a significant role in eliminating malaria. A team of over 200 members will be part of the implementation of this demonstration project.

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>